Failure to suppress irrelevant brain activity in Alzheimer diseaseSeptember 20, 2005Some people close their eyes when they listen to music, others wear earplugs when they read in noisy places. Both serve to block out inappropriate sensory stimulation, something that happens automatically when we concentrate. A study by Alexander Drzezga and colleagues (of the Technical University Munich, Germany) to be published in the international open access journal PLoS Medicine now shows that this focusing process is defective in people with Alzheimer disease (AD). Earlier brain imaging studies have shown how the focusing process works in healthy people: When they undergo tasks that depend exclusively on visual clues, they not only activate the areas of the brain involved in visual processing but also de-activate those areas that have to do with auditory processing. The reverse activation/deactivation pattern is seen when the clues are exclusively auditory. The phenomenon, called "cross-modal auditory/visual deactivation," is thought to help with focusing the information processing capacities of the brain on the relevant areas. To test whether cross-modal inhibition is affected in AD, Drzezga and colleagues examined the activation and deactivation patterns in the brains of patients with AD and individuals with mild cognitive impairment (MCI). The researchers tested 32 participants: 11 healthy individuals, 11 individuals with mild cognitive impairment, and 10 individuals with moderate AD. The participants were trained to perform a navigation task, based exclusively on visual clues, in a virtual reality environment. All participants understood the task and the clues. They then each completed 12 separate PET scans, 8 during active navigation (finding their way from a start point to a specific destination) and 4 under control conditions (traveling along a never-ending pathway). The tasks were performed in complete silence. The three groups differed in their performance-measured by the time needed to reach the destination-as would be expected. In the scans, the researchers saw significant differences in brain activation patterns, but most striking were differences in the ability to inhibit irrelevant activity: Healthy individuals showed strong bilateral deactivation in the auditory cortex. Auditory deactivation was much less prominent in individuals with MCI, and totally absent in individuals with AD. Drzezga and colleagues propose that the patients' orientation disability in the outside world may be partially caused by their inability to selectively focus brain activity in task-relevant areas. They are now in the middle of a follow-up study that concentrates on individuals with MCI-some of whom remain stable for years whereas others progress to AD-to see whether the extent of cross-modal inhibition correlates with progression to disease. Preliminary results suggest that it does. Public Library of Science |
|||||||||||||||||||||
| Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Delirium in hospitalized adults: Situation critical, no relief available Every year as many as seven million adults in the United States experience delirium during hospitalization. New data demonstrate potential for early detection of Alzheimer's disease Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease. Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH). Measuring brain atrophy in patients with mild cognitive impairment Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease. Commonly used medications may produce cognitive impairment in older adults Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults. Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug. New test for mysterious metabolic diseases developed at Stanford/Packard Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism. Recalibrating 'fight or flight' A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology Vitamin B does not slow cognitive decline in Alzheimer's A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease. Protecting patient privacy the new fashioned way Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act. More Alzheimer Disease Current Events and Alzheimer Disease News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||